PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the ...

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced today that the U.S. Food and ...

Six abstracts to be presented highlighting results of AJOVY preventive treatment in patients with migraine Oral presentation will feature data from the UNITE study showing that AJOVY significantly ...

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY ® ...

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in ...

Treatment with fremanezumab led to a significantly greater reduction in monthly migraine days and monthly headache days. The Food and Drug Administration (FDA) has approved Ajovy ® (fremanezumab-vfrm) ...

Please provide your email address to receive an email when new articles are posted on . Ajovy offers “significant efficacy” compared with placebo to address episodic migraine in children and ...

Health Canada approves Pr AJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 ...

CINCINNATI (WKRC) - A medication previously available only for adults is now on the market for children to help reduce migraines. Recent research focused on children aged six to 17 and examined a ...